Tris Pharma Wins Patent Case Over Copycat ADHD Drug by Teva Unit

A federal judge ruled that a generic version of an extended-release liquid treatment for Attention-Deficit/Hyperactivity Disorder made by Teva’s Actavis unit infringed a patent for Tris Pharma’s Quillivant XR medication.

• U.S. District Judge Colm Connolly agreed with Tris that Teva’s copycat meets the patent’s “single mean peak” limitation, according to opinion issued Monday in federal court in Wilmington, Delaware
  • Judge also rejected Teva’s contention that the patent shouldn’t have been issued
• Case, which started in 2014, was remanded to trial court after U.S. Court of Appeals for the Federal Circuit’s November 2018 ruling that a Delaware judge’s invalidation ...